The purpose of our study was to evaluate the clinical characteristics, recurrence patterns, surgical management and outcomes, and to identify factors which may affect the survival of early-stage AGCT patients operated at our gynecological oncology department.
MATERIAL AND METHODS
Our study was retrospectively performed at the Istanbul Kanuni Sultan Suleyman Training and Research Hospital's Gynecological Oncology Department, after obtaining approval from the local ethics committee (KSSTRH, 2018/11/60) with the Declaration of Helsinki.
The hospital database and patient files were thoroughly reviewed. All the patients with earlystage-AGCTs (stage I-II), who were treated between January 1998 and December 2015, were included in our study.
The patients with any other accompanying malignancy and those in the advanced stage (stage III-IV) of AGCT were excluded. Using the hospital database, demographic and clinical characteristics of the patients, including pre-operative CA-125 levels, ultrasound images, surgical techniques, tumor sizes, lymph node involvement, and surgical stage at diagnosis were recorded. Age and tumor size were evaluated for multivariate analysis. Furthermore, recurrence, ACT, and postoperative follow-up outcomes were evaluated. The accuracy of frozen sections (FS) was evaluated in comparison to intraoperatively-performed FS. Patients with incomplete data were excluded from the analysis.
Regarding recurrent cases, parameters such as time to recurrence, additional treatment modalities, and status after recurrence were also recorded. Recurrent and non-recurrent groups were compared based on the prognostic parameters. Operations were classified as fully staged, incompletely staged, or un-staged. The operation was considered fully staged if peritoneal washing and complete pelvic as well as para-aortic lymphadenectomy were performed. If only pelvic lymphadenectomy was performed or an inadequate number of lymph nodes were removed, the patients were considered incompletely staged. If only ovarian cystectomy or oophorectomy and/or hysterectomy were performed, the patients were considered un-staged. Adequate lymph node count for the fully staged procedure was defined as at least 40 lymph nodes (25 of pelvic and 15 of para-aortic lymph nodes). 14 Disease-free survival (DFS) was defined as the time from the date of primary surgery to the detection of recurrence, or the latest observation in patients without recurrence. Overall survival (OS) was defined as the time from the date of primary surgery to death, or the latest observation.
All the statistical analyses were performed using the software Med-Calc (ver. 16 .0 for Windows, MedCalc Software, Mariakerke, Belgium). Chisquare test and Student's t-test were used for statistical analysis of unpaired data. Analysis of survival was based on the Kaplan-Meier method, and the results were compared using a log-rank test. Univariate and multivariate Cox regression analyses were used to determine factors affecting survival and were presented as hazard ratios (HR). A p-value of <0.05 was considered to be statistically significant.
RESULTS
Forty-one patients with AGCTs were found to meet the study criteria. The clinicopathological characteristics of the patients are presented in Table 1 . Median age at diagnosis was 51.4 years. Mean tumor diameter was 81.7 mm. Abdominal or pelvic pain (61%) were the most commonly reported symptoms, followed by irregular menstruation (29.3%). Preoperative endometrial pathology results of 34 patients were available. Among these, eight had endometrial hyperplasia with or without atypia ( Table 1) .
Surgery was performed as the primary treatment. Detailed surgical and pathological characteristics of the patients are demonstrated in Table 2 . Twenty-three cases (56%) underwent full-staged surgery including total abdominal hysterectomy (TAH), bilateral salphingo-opherectomy (BSO), pelvic and para-aortic lymphadenectomy, while 16 cases (39.1%) underwent incomplete-staged procedure including TAH, BSO, and pelvic lymphadenectomy, and the remaining two patients (4.9%) underwent TAH and BSO procedures only. We observed that the majority of the fully or incompletely staged patients had stage IA disease (26 cases, 63.4%), while 17.1% had stage IC and 14.6% had stage II disease. FS was performed in only 32 patients and its accuracy was 75%. The median follow-up period was 55.2 months (range 1-168 months). During the follow-up period, three patients (7.3%) died of the disease. A total of eight patients received ACT after initial surgery ( Table 2 ).
According to the multivariate analyses, FIGO stage (<IC or ≥IC), age (≥43.5 or 43.5>), and lymphadenectomy in addition to full stage surgery did not influence the DFS or OS (Table 3 ). In the univariate analyses, age, bilaterality, tumor size, and Baki preoperative ultrasound image (solid or not solid) were not observed to influence the involvement of lymph nodes in AGCTs (Table 4 ).
According to the multivariate analyses, FIGO stage (<IC or ≥IC), surgical staging, and CT did not influence the recurrence of AGCTs ( Table 5 ).
The average DFS was 35 months. Three of the four recurrences appeared during the first ten months. Three patients with recurrent disease were treated with chemotherapy and one was treated with chemotherapy after secondary surgery. Three patients were managed by only salvage chemotherapy with paclitaxel and carboplatin. The clinical characteristics of cases with recurrent AGCT are presented in Table 6 .
DISCUSSION
In this study, we evaluated women with early-stage AGCT, who were managed at a tertiary gynecological oncology clinic in Turkey. We observed that parameters such as age, stage, tumor size, and lymphadenectomy were not independent prognostic predictor factors in AGCTs.
AGCTs are uncommon clinical entities, constituting nearly 5% of all ovarian neoplasia. 1,2 Ovarian AGCTs may occur at an earlier age and the diagnosis can be made at earlier stages because of the slow proliferation rates of these tumors. They recur late, and the disease prognosis is good. 3, 4 However, because of the slow proliferation rate of these tumors, it is difficult to clearly understand the clinical scenario of AGCT, decide on the appropriate treatment, and identify its prognostic factors. The median age for the diagnosis of this tumor is around 50-55 years. 5 In our study, the median age at diagnosis was 51 years, which was in accordance with that reported in the literature. Although AGCT may be asymptomatic, Sun et al. demonstrated that most patients with AGCTs exhibited symptoms due to the mass-like abdominal distension or symptoms related to the hormone production of these tumors, which were similar to the findings of our study. 8 In our study, most of the patients (85.4%) were diagnosed at stage I and the mean tumor diameter at the time of diagnosis was 8.1 cm.
The requirement of complete systematic lymphadenectomy during primary surgery and the prognostic factors for OS and DFS in patients are the most commonly discussed issues about AGCTs. In the previous studies, FIGO stage, tumor diameter, tumor rupture (preoperative or intraoperative), age at diagnosis, mitotic index, surgical method (staged or not), and residual disease after surgery were shown to be the prognostic factors in AGCTs. 9, 10, [15] [16] [17] [18] In studies with large sample sizes, FIGO stage, tumor size, nuclear atypia, and postoperative residual tumor have been reported to be the major prognostic factors. 7, 8, 19 In this study, we evaluated only 41 patients with ovarian AGCTs that were treated in our gynecological oncology department. As a result, FIGO stage (<IC or ≥IC), age (≥43.5 or 43.5>), lymphadenectomy, and full-staged surgery were not found to be significant prognostic predictors in the multivariate analyses for OS and DFS. Furthermore, we observed that the rate of lymph node involvement in recurrence was 25% and all the nodal involvements were in the para-aortic area. The involvement of retroperitoneal lymph nodes in recurrence of AGCTs was reported to be 15% by Abu-Rustum et al. 8, 10, 20, 21 In the study by Abu-Rustum et al., 81% of the patients were not completely staged. The authors suggested full-staged surgery and complete systematic lymphadenectomy, as recurrences appeared to be because of the involvement of microscopic lymph nodes. 10 In contrast, we observed that full-staged surgery was not a significant prognostic factor for AGCTs. Therefore, in light of our findings, we believe that full surgical staging does not change the prognosis.
Another contentious issue for AGCTs is the use of ACT after surgery. According to the National Comprehensive Cancer Network (NCCN), the treatment recommended after comprehensive staging is the observation or consideration of platinumbased chemotherapy for stage IC, and platinumbased chemotherapy or radiotherapy for the limited disease for stages II-IV, Sun et al. and Homesley et al. demonstrated that ACT was necessary for the prevention of recurrent disease. 8, 22, 23 However, Al-Badawi et al. showed that ACT had no benefit for advanced stage disease. 24 Furthermore, Chan et al. reported that the absence of residual disease was an independent predictor of improved survival and ACT did not affect survival. 25 In our study, surgery after ACT did not influence the rate of survival or the recurrence in comparison to surgery without ACT.
In the present study, two out of 35 stage I patients (5.7%) and two out of 6 stage II patients (33.3%) showed recurrent disease. However, according to the multivariate analysis, the surgical stage was not an independent prognostic factor. Furthermore, we showed that surgical staging and ACT were not independent risk factors for the recurrence of AGCTs. In the literature, the pelvic region has been reported to be the most common site for disease recurrence (16.2-77.4%), while the liver is shown to be the most common extra-pelvic region for metastasis (6-25%). 8, 9, 11, 16 In our study, the liver was found to be the most common site for the first recurrence (100%). The rate of pelvic metastases was 0%. These results may possibly be due to the more effective measures taken against local recurrence.
Our study has some limitations, primarily because of its retrospective nature. Secondly, we could not investigate the mitotic index level in the possible prognostic factors for AGCT. Nevertheless, this study evaluated AGCT patients in the early stages of the disease and the follow-up periods of the patients were long.
CONCLUSION
FIGO stage, age, lymphadenectomy, and full-staged surgery do not influence DFS, OS, or recurrence in early-stage AGCT. Furthermore, age, bilaterality, and preoperative ultrasound image were not independent risk factors for lymph node involvement in AGCTs. Because of the rare occurrence of ovarian AGCTs, more multicenter studies with larger sample sizes are required to determine the possible prognostic factors and strategies for their ideal management.
S So ou ur rc ce e o of f F Fi in na an nc ce e
During this study, no financial or spiritual support was received neither from any pharmaceutical company that has a direct connection with the research subject, nor from a company that provides or produces medical instruments and materials which may negatively affect the evaluation process of this study. 
